SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for Bysanti, a new treatment for bipolar I disorder and schizophrenia, which was granted New Chemical Entity (NCE) status with patent protection extending to 2044. The community is actively discussing this as a major re-rating catalyst, anticipating significant institutional buying, and speculating on the drug's blockbuster potential alongside future pipeline developments.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid renewed uncertainty surrounding global trade policy, driven by recent tariff decisions that have sparked market volatility. The community is sharply divided, with bears anticipating a major downturn following weekend declines, while bulls expect a typical 'V-shape' recovery, particularly ahead of key tech earnings this week.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The recent acquisition of Astria Therapeutics, integrating the late-stage HAE drug navenibart, is driving BioCryst's conversation, especially with new data presentations for navenibart and Orladeyo expected at a medical conference and upcoming earnings. The community is actively discussing the potential of these pipeline advancements against persistent concerns about the stock's valuation and significant short interest.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending after receiving a prestigious Lightwave Award for its Teralight 1.6T product, intensifying community speculation for imminent major customer orders or partnerships in AI data center optical interconnects, even as some investors express frustration over management's continued silence and past capital raises.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF is trending with active debate around the Supreme Court's impending tariff ruling, as investors weigh the potential for a small-cap breakout if trade barriers ease against risks of new tariffs or wider market volatility. This uncertainty is fueling diverse technical outlooks and notable options hedging, highlighting its role as a key sentiment indicator.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohen's recent cryptic social media posts are driving intense speculation among investors about an imminent, monumental acquisition or strategic move, leveraging GameStop's substantial cash reserves. This dynamic fuels a fierce debate between ardent holders anticipating a massive short squeeze and skeptics citing ongoing price suppression and the absence of concrete company details.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to the expanding deployment of its driverless robotaxi services with Uber across the Middle East and the successful market entry of its WePilot ADAS system with major automotive OEMs, generating significant revenue growth and improved margins in its latest earnings report. The community actively discusses the stock's perceived undervaluation compared to its global operational achievements and increasing institutional backing, offset by a desire for more explicit near-term financial guidance from management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compass Diversified (CODI) Expected to Announce Quarterly Earnings on Thursday

Compass Diversified (NYSE:CODI) will be releasing earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Compass Diversified (NYSE:CODI) Trading 7% Higher - Here's What Happened

Compass Diversified (NYSE:CODI) Trading 7% Higher - Here's Why...

Compass Diversified (NYSE:CODI) Stock Crosses Above 200 Day Moving Average - Here's Why

Compass Diversified (NYSE:CODI) Share Price Passes Above 200-Day Moving Average - Here's What Happened...

Compass Diversified Holdings (NYSE:CODI) Given Consensus Recommendation of "Hold" by Analysts

Compass Diversified Holdings (NYSE:CODI - Get Free Report) has earned an average rating of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. Two investment...

Compass Diversified (NYSE:CODI) Price Target Cut to $13.00 by Analysts at B. Riley

B. Riley dropped their price objective on shares of Compass Diversified from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday...

Compass Diversified (NYSE:CODI) Stock Rating Lowered by Zacks Research

Zacks Research cut shares of Compass Diversified from a "hold" rating to a "strong sell" rating in a research note on Monday...

Compass Diversified (CODI) Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Compass Diversified Holdings Q3 Loss Rises

(RTTNews) - Compass Diversified Holdings (CODI) released Loss for its third quarter of -$73.49 million...

Compass Diversified Q3 Earnings Call Highlights

Compass Diversified (NYSE:CODI) used its third-quarter 2025 conference call to mark a return to regular reporting and to outline how the company is operating after completing the Lugano...

Insights Ahead: Compass Diversified Hldgs's Quarterly Earnings

Compass Diversified Holdings, a traded fund in New York Stock Exchange, seeks investment opportunities in small and middle-market companies located in North America with an enterprise value of USD 10-100 million and an annual EBITDA of at least USD 20 million. The fund targets companies operating in industrial and branded consumer sectors. It provides financing for acquisitions, buyouts, and later-stage capital requirements with transaction size ranging from USD 200-800 million utilizing debt and equity. It takes controlling interests and makes investments in public companies.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.04	--	--	N/A
Q3 '25	$0.61	-$0.98	-260.35%	MISSED
Q2 '25	$0.57	-$0.27	-147.61%	MISSED
Q1 '25	$0.45	-$0.36	-180.50%	MISSED
Q4 '24	$0.56	$0.62	9.95%	BEAT

CODI
Compass Diversified Holdings

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CODI News

CODICompass Diversified Holdings